US DOT Shuts Down Trucking Company for Safety Violations

    A Laredo, Texas based company is shut down by the US Department of Transportation (US DOT) for repeated and significant safety violations.  After a crash in mid-August, 2013, the Federal Motor Carrier Safety Administration (FMCSA) instituted an investigation of the company, REDCO Transport.  The investigation found serious and significant safety violations by not only the Continue Reading

    FURLOUGHED GOVERNMENT WORKERS RECALLED TO INVESTIGATE OXYELITE PRO

    ABC and CBS News are reporting that the US Food and Drug Administration has recalled “a couple” of technical experts to help investigate the hepatitis outbreak in Hawaii for a possible link to the dietary supplement OxyElite Pro.  The FDA is prioritizing the work of its investigators who have not been furloughed to investigate matters Continue Reading

    CDC Health Advisory Issued Due to Hepatitis Outbreak Linked to OxyElite Pro

    Summary: On October 8, 2013, the Center for Disease Control and Prevention (“CDC”) issued a Health Advisory for OxyElite Pro due to reports of acute hepatitis cases linked to the product’s use.  A number of previously healthy individuals developed acute hepatitis and sudden liver failure of unknown cause after using OxyElite Pro for weight loss Continue Reading

    FDA Finalizes New System to Identify Medical Devices

    According to an FDA news release posted on September 20, 2013, the U.S. Food and Drug Administration (“FDA”) is launching a new system for identifying high-risk medical devices such as hip and knee implants.  The agency announced that its new Unique Device Identification System (UDI) will provide a consistent and simpler way to identify medical Continue Reading

    F.D.A. Requires Drug Manufacturers to Change Labels and Warn of Risk of Nerve Damage for Patients taking Oral and Injectable Fluoroquinolone Drugs

    Summary On August 15, 2013, the U.S. Food and Drug Administration (F.D.A.) issued a safety announcement advising the public that manufacturers of fluoroquinolone drugs are required to change drug labels to provide a more adequate warning to patients of the risk of permanent nerve damage that may be associated with taking these kinds of drugs.